SCHEDULE: Vanguard Reports 0% Stake in Tonix Pharmaceuticals
Beneficial Ownership Update
The Vanguard Group's beneficial ownership in Tonix Pharmaceuticals Holding Corp. has dropped to 0% following an internal realignment.
Summary
- The Vanguard Group filed an Amendment No. 2 to Schedule 13G for Tonix Pharmaceuticals Holding Corp.
- The filing reports that The Vanguard Group now holds 0% beneficial ownership of Tonix Pharmaceuticals' Common Stock.
- This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
- In accordance with SEC Release No. 34-39538, certain Vanguard subsidiaries or business divisions will now report beneficial ownership separately.
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities held by these disaggregated entities.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. The change in beneficial ownership is explicitly attributed to an internal administrative realignment within The Vanguard Group, not a reflection of Tonix Pharmaceuticals' operational or financial performance.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Tonix Pharmaceuticals Holding Corp.'s future performance or operations.
Industry Context
StockSavvy.ai notes that while a major institutional investor like The Vanguard Group reducing its stake to 0% might typically raise concerns, the explicit explanation of an 'internal realignment' suggests this is an administrative change within Vanguard's reporting structure rather than a strategic divestment based on Tonix Pharmaceuticals' performance or outlook. This distinction is crucial for market interpretation.
Stakeholder Impact
- Shareholders of Tonix Pharmaceuticals Holding Corp. may observe a change in the institutional ownership structure, with The Vanguard Group no longer directly reporting beneficial ownership. However, the explanation of an internal realignment suggests no direct negative impact on the company's fundamentals or share value from this specific event.
Key Dates
| Date | Description |
|---|---|
| January 12, 2026 | Date of internal realignment within The Vanguard Group, Inc. |
| 03/13/2026 | Date of event which requires filing of this statement (beneficial ownership change). |
| 03/27/2026 | Date of filing and signature by The Vanguard Group. |
Keywords
Tonix Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, TNXP
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.